Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal.
Maji A, Soutar CP, Zhang J, Lewandowska A, Uno BE, Yan S, Shelke Y, Murhade G, Nimerovsky E, Borcik CG, Arango AS, Lange JD, Marin-Toledo JP, Lyu Y, Bailey KL, Roady PJ, Holler JT, Khandelwal A, SantaMaria AM, Sanchez H, Juvvadi PR, Johns G, Hageman MJ, Krise J, Gebremariam T, Youssef EG, Bartizal K, Marr KA, Steinbach WJ, Ibrahim AS, Patterson TF, Wiederhold NP, Andes DR, Pogorelov TV, Schwieters CD, Fan TM, Rienstra CM, Burke MD. Maji A, et al. Among authors: patterson tf. Nature. 2023 Nov;623(7989):1079-1085. doi: 10.1038/s41586-023-06710-4. Epub 2023 Nov 8. Nature. 2023. PMID: 37938782 Free PMC article.
Erratum for Wiederhold et al., "The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate)".
Wiederhold NP, Patterson TF, Rebholz S, Brennan J, Patton T, Barrett J, Boal CWC, Ehrensberger M, Boyle R, Cushion MT. Wiederhold NP, et al. Among authors: patterson tf. Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0147522. doi: 10.1128/aac.01475-22. Epub 2023 Jan 16. Antimicrob Agents Chemother. 2023. PMID: 36645296 Free PMC article. No abstract available.
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Gebremariam T, et al. Among authors: patterson tf. Antimicrob Agents Chemother. 2024 May 2;68(5):e0154523. doi: 10.1128/aac.01545-23. Epub 2024 Apr 1. Antimicrob Agents Chemother. 2024. PMID: 38557112
Update on Outbreak of Fungal Meningitis among U.S. Residents who Received Epidural Anesthesia at Two Clinics in Matamoros, Mexico.
Smith DJ, Gold JAW, Chiller T, Bustamante ND, Marinissen MJ, Rodriquez GG, Cortes VBG, Molina CD, Williams S, Vazquez Deida AA, Byrd K, Pappas PG, Patterson TF, Wiederhold NP, Thompson Iii GR, Ostrosky-Zeichner L; Fungal Meningitis Response Team. Smith DJ, et al. Among authors: patterson tf. Clin Infect Dis. 2023 Sep 22:ciad570. doi: 10.1093/cid/ciad570. Online ahead of print. Clin Infect Dis. 2023. PMID: 37739479
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies.
Young JH, Andes DR, Ardura MI, Arrieta A, Bow EJ, Chandrasekar PH, Chen SCA, Hammond SP, Husain S, Koo S, Lavergne V, Nguyen MH, Patterson TF, So M, Thompson GR, Morrissey CO, Schuster MG. Young JH, et al. Among authors: patterson tf. Open Forum Infect Dis. 2024 Feb 6;11(3):ofae082. doi: 10.1093/ofid/ofae082. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38481428 Free PMC article. Review.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG, Rebolledo PA, Mourad A, Lindsell CJ, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Bramante CT, Lenert LA, Lim S, Williamson JC, Cardona OQ, Scott J, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Rothman RL, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Stewart TG, et al. JAMA. 2023 Dec 26;330(24):2354-2363. doi: 10.1001/jama.2023.23363. JAMA. 2023. PMID: 37976072
274 results